Following the leach testing for antimony, the residual tailings were utilized for cyanide shake tests for gold extraction.
Data showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related to dose-limiting ...
ROME — Rome Health will open its new 18-bay Preoperative and Postoperative Procedure unit adjacent to the Kaplan Center for ...
Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...
The questions on caste to be asked by enumerators will be notified before the commencement of the second phase of the Census ...
Early biomarker and safety data show encouraging signals with plans to present additional data in 2H 2026 AviadoBio secures ...
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer ...
Ad hoc announcement pursuant to Art. 53 LR Phase 2 results show a statistically significant dose-dependent response on total sleep time with clinically meaningful improvements across multiple sleep ...
Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that St. Michael’s Hospital (SMH), part of Unity Health Toronto, has commenced patient dosing in ...
Census 2027 data collection begins soon. Individual information remains confidential under law. The census will be conducted ...
NASA’s Artemis II SLS (Space Launch System) rocket lifted off from Launch Complex 39B in Florida at 6:35 p.m. EDT, marking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results